Kaitlyn Bader, Senior Editor

Catch up on coverage from the last day of the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

The phase 3b/4 LEVEL-UP study assessed adolescents and adults with moderate to severe atopic dermatitis.

Roflumilast cream 0.15% is being evaluated for patients with mild to moderate atopic dermatitis down to 6 years.

Raj Chovatiya, MD, PhD, discusses how approved AD therapeutics currently address itch and whether any therapeutics will eventually have a remittive effect.

David Rosmarin, MD, shares key points from phase 3 data of ruxolitinib for vitiligo, as well as highlights the potential for targeting the STAT pathway in upcoming atopic dermatitis therapeutics.

Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.

Robert Sidbury, MD, MPH, addresses the similarities and differences between the AAD’s recent atopic dermatitis guidelines and other guidelines from various groups and countries.

Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.

Catch up on coverage from the first day of the 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, Illinois.

Karan Lal, DO, dives into the benefits of combination therapy for vitiligo with topicals and devices.

Jonathan Silverberg, MD, PhD, MPH, presented his tips for effectively treating atopic dermatitis without worsening autoimmune comorbidities.

Improvements in patient-reported outcomes were higher among patients treated with upadacitinib 30mg versus 15mg.

Nanette Silverberg, MD, shares data on the efficacy of on- and off-label therapeutics for vitiligo, as well as the importance of communication with patients to promote clinical excellence.

Jonathan Silverberg, MD, PhD, MPH, shares insights into the change of this year’s meeting and the benefit of additional disease states.

Nanette Silverberg, MD, shares her excitement about the inclusion of vitiligo at this year’s RAVE meeting.

The inaugural RAVE conference begins today in Chicago, Illinois.

This week’s collection of the latest dermatologic studies includes the use of digital communication for patients with hidradenitis suppurativa (HS), rituximab for pediatric patients with pemphigus, a case report of primary oral extramammary Paget disease, and the efficacy and safety of LAight therapy for HS.

Zabinski, vice president and head of commercial strategy and AI at OM1, discusses the evolving role of AI in dermatology, focusing on its potential and challenges in skin cancer detection.

Phase 3 trials have been initiated in patients with high-risk melanoma.

Raj Chovatiya, MD, PhD, reviews the varying degrees of influence of skin barrier disruption, immune dysregulation, and Malassezia yeast in seborrheic dermatitis.

The phase 2 study achieved the primary end point of a >30% Severity of Alopecia Tool score improvement.

Chovatiya was a lead author of the latest seborrheic dermatitis and roflumilast foam review published in the Journal of Clinical and Aesthetic Dermatology.

Learn more about the in-depth topics covered in the May 2024 supplement of Dermatology Times.

Learn more about the in-depth topics covered in the May 2024 print issue of Dermatology Times.

The month of May has been full of pipeline news, including updates on VYN201 for nonsegmental vitiligo, imsidolimab for GPP, sonelokimab for HS, and more.

In case you missed it, this week we had news about results from BE HEARD I and BE HEARD II published in The Lancet, AbbVie's Clearly Me Campaign, the role of HIF-1-alpha in inflammation and psoriasis, and more.

The Lancet data is the primary publication of bimekizumab results from BE HEARD I and BE HEARD II.

The new action date is December 29, 2024.

Andrew Baker, MBA, MPAS, PA-C, discusses his role in skin cancer detection and advice for PAs interested in skin surgeries and Mohs closures.

This week’s collection of the latest dermatologic studies includes case reports of onychocytic matricoma, congenital triangular alopecia treated with 5% topical minoxidil, systemic therapy usage in vulvar lichen sclerosus and vulvovaginal lichen planus, and dose escalation of interleukin inhibitors in Japanese patients with psoriasis.